E-Mail
The COVID-19 pandemic has been shown to have caused a significant strain on the healthcare system and resources in the United States. However, data regarding the impact of the virus on hip fractures, primarily seen in elderly patients, is lacking.
Researchers at Hospital for Special Surgery (HSS) sought to compare characteristics and outcomes of hip fracture patients admitted during the COVID-19 outbreak to patients admitted before the outbreak. They also examined characteristics and outcomes of hip fracture patients with and without the virus. Their findings were presented at the 2021 Spring American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Meeting.1
E-Mail
Interim results of a study conducted by researchers at Hospital for Special Surgery (HSS) suggest that oral tranexamic acid (TXA) is non-inferior to intravenous (IV) TXA in preventing blood loss in total knee and total hip replacement surgery. These findings were presented at the 2021 Spring American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Meeting.1
Previously available information suggests that oral, IV and topical TXA are all effective at reducing blood loss and drastically reducing blood transfusion rates during and after surgery, but research with direct comparisons for each method is limited. TXA in orthopedic surgery has become the standard of care. However, the most efficient, efficacious and cost effective method of administration remains unknown, said principal investigator Stavros Memtsoudis, MD, PhD, MBA, an anesthesiologist at HSS. The oral administration of TXA is logistically easier, thus reducing the risk of drug errors in the OR.
E-Mail
In a study conducted by researchers at Hospital for Special Surgery (HSS), cumulative opioid use was reduced by 30% in a patient group that received duloxetine after total knee arthroplasty (TKA) compared with patients who received placebo. Patients who received duloxetine also reported higher pain management satisfaction and less pain interference with mood, walking, normal sleep, and work activities. These findings were presented at the 2021 Spring American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Meeting.
1
Studies have demonstrated that many patients report joint pain two weeks after TKA.
2 Given the status of the ongoing opioid epidemic, it is critical to study safe and effective alternative pain treatments.
Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR® (Methylnaltrexone Bromide) At ASRA s 46th Annual Spring Meeting
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ Salix Pharmaceuticals ( Salix ), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that two RELISTOR® (methylnaltrexone bromide) scientific posters will be presented at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting being held May 13 – 15, 2021. The meeting is hosted by The American Society of Regional Anesthesia and Pain Medicine (ASRA).
The following posters will be presented on Thursday, May 13 from 10:30 a.m. – 12:00 p.m. ET: